Resumo

CARRILLO-ESPER, Raúl et al. Recombinant factor VII activated in non-hemophiliac patients with acute severe hemorrhage in the intensive care unit. Gac. Méd. Méx [online]. 2006, vol.142, n.5, pp.369-376. ISSN 2696-1288.

Background. Severe hemorrhage is a frequent complication with multiple etiologies and high morbi-mortality observed among critically ill patients. Recombinant Factor VIIa (rFVIIa) constitutes a new therapeutic alternative. Objective. Analyze the evolution in a non-hemophiliac patient group with severe hemorrhage treated with rFVIIa. Material and Methods. Ten non-hemophiliac patients with severe hemorrhage, five men and five women between 18 and 74 years, were included and treated with rFVIIa. We used a t test for statistic analyses. Significance was set at p < 0.001. Results. Among patients treated with rFVIIa, hemorrhage was controlled and the use of blood products was significantly diminished (p < 0.001). Coagulation tests, fibrinogen levels, platelet count and perfusion parameters increased significantly (p < 0.001). Conclusions. rFVIIa is a therapeutic alternative for the treatment of severe hemorrhage not controlled by conventional management.

Palavras-chave : Recombinant Factor VIIa; severe hemorrhage; coagulation cell model.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )